Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zenas BioPharmaZBIO +1.04%8 PS Ratio is 1,844.38 as of Aug. 15, 2026, which is 2671% above its 10-year median of 66.56. GuruFocus rates ZBIO with a GF Score™ of 8/100. The stock has 1 warning sign investors should review. Among 931 Biotechnology companies, Zenas BioPharma ranks worse than 86.9% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Zenas BioPharma's share price is $29.51.
Zenas BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02. Hence, Zenas BioPharma's PS Ratio for today is 1,844.38.
The historical rank and industry rank for Zenas BioPharma's PS Ratio or its related term are showing as below:
ZBIO'
s PS Ratio Range Over the Past 10 Years
Min: 3.11 Med: 66.56 Max: 1844.38
Current: 1844.38
During the past 4 years, Zenas BioPharma's highest PS Ratio was 1844.38. The lowest was 3.11. And the median was 66.56.
ZBIO's PS Ratio is ranked worse than 86.9% of 931
companies
in the Biotechnology industry
Industry Median: 9.55
vs ZBIO: 1844.38
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Zenas BioPharma PS Ratio Related Terms
Zenas BioPharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Zenas BioPharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zenas BioPharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zenas BioPharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zenas BioPharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Zenas BioPharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Zenas BioPharma's Share Price of today is $29.51. Zenas BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Zenas BioPharma (ZBIO) has a PS Ratio of 1,844.38 as of Aug. 15, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zenas BioPharma and its competitors. This is 2671% above median its historical median of 66.56. Over the past decade, Zenas BioPharma's PS Ratio has ranged from 3.11 to 1,844.38. According to the industry distribution chart, Zenas BioPharma ranks #809 out of 931 companies in the Biotechnology industry, placing it in the top 86.9%.
Is Zenas BioPharma's PS Ratio too high?
Zenas BioPharma's current PS Ratio of 1,844.38 is 2671% above median its 10-year median of 66.56. Over the past 10 years, this metric has ranged from a low of 3.11 to a high of 1,844.38. The Biotechnology industry median PS Ratio is 9.55. Zenas BioPharma's value of 1,844.38 is 19212.9% above this industry median. Based on the distribution chart, Zenas BioPharma ranks #809 out of 931 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zenas BioPharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's PS Ratio compare to ADMA and PGEN?
According to the Biotechnology industry distribution chart, Zenas BioPharma ranks #809 out of 931 companies for PS Ratio. This places Zenas BioPharma in the lower half of its industry. The industry median PS Ratio is 9.55. Zenas BioPharma's value of 1,844.38 is 19212.9% above this benchmark. Historically, Zenas BioPharma's own PS Ratio has ranged from 3.11 to 1,844.38 over the past decade. While the company's 10-year median is 66.56 vs. the industry median of 9.55, Zenas BioPharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.55, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zenas BioPharma's current PS Ratio of 1,844.38 is 19212.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Zenas BioPharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zenas BioPharma's current PS Ratio is 1,844.38, which is 2671% above median its own 10-year median of 66.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current PS Ratio of 1,844.38. The current PS Ratio is 1,844.38, which is 2671% above median its 10-year median of 66.56 and 19212.9% above the Biotechnology industry median of 9.55. Zenas BioPharma's overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current PS Ratio is 1,844.38 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
8GF Score
Get the complete analysis for ZBIO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZBIO has been successfully added to your 
